Search
Canakinumab
go.drugbank.com/drugs/DB06168ApprovedInvestigationalCanakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. … It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated.
Categories: Interleukin-1 BlockersProducts: IBECTA 150 MG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 4 ADET, IBECTA 150 MG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 1 ADETTGAAC94
go.drugbank.com/drugs/DB06175InvestigationaltgAAC94 is a recombinant adeno-associated virus serotype 2 (AAV2) vector containing the cDNA for a human tumor necrosis factor receptor (TNFR)-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene. … The Health Recombinant DNA Advisory Committee (RAC) concluded that a possible role of the gene transfer in this clinical course could not definitively be excluded due to the lack of data. [A264038]
AEG35156
go.drugbank.com/drugs/DB06184InvestigationalAEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. … A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity.
Ipilimumab
go.drugbank.com/drugs/DB06186ApprovedInvestigationalIpilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). … [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Categories: Immunoglobulin G, CTLA-4-directed Blocking AntibodyProducts: YERVOY®5 MG /ML SOLUCION INYECTABLE PARA INFUSION INTRAVENOSA, YERVOY 5 mg/ml concentrate for solution for infusionSeliciclib
go.drugbank.com/drugs/DB06195InvestigationalR-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated … Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation
Categories: Heterocyclic Compounds, 2-RingSynonyms: 2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine, R-roscovitineAtrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigationalAtrasentan is a novel, selective endothelin A receptor antagonist (SERA). … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsTedisamil
go.drugbank.com/drugs/DB06200ExperimentalIt is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration. … Tedisamil (planned trade name Pulzium) is an investigational drug for atrial fibrillation and atrial flutter.
Categories: Compounds used in a research, industrial, or household settingLasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnIt gained approval by European Commission in March 2009. … Later Fablyn was developed as a result of a research collaboration between Pfizer and Ligand Pharmaceuticals with a newly submitted New Drug Application in 2008.
Categories: Heterocyclic Compounds, 1-RingSynonyms: (-)-cis-5,6,7,8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol